Table 1.
Demographical and virological patients’ characteristics at baseline.
| Total cohort (n=56) |
Baseline HBeAg(+) patients (n=37) |
Baseline HBeAg(–) patients (n=19) |
p value | |
|---|---|---|---|---|
| Agea,b (years) | 29 (25–41) | 27 (23–33) | 39 (30–44) | 0.0004 |
| Viral genotypec | ||||
|
B C |
13 43 |
11 26 |
2 17 |
ns |
| Baseline serum HBV DNAa,b (IU/mL) | 1.2 × 108 (1.4 × 106–7 × 108) | 2.1 × 108 (2.7 × 107–1.2 × 109) | 2.2 × 106 (2.8 × 105–5.4 × 108) | ns |
| Baseline ALT levela,b (IU/L) | 1.6 × 102 (9.4 × 101–2.6 × 102) | 1.6 × 102 (1 × 102–2.5 × 102) | 1.3 × 102 (6.2 × 101 3.4 × 102) | ns |
| Duration of telbivudine treatmenta,b (weeks) | 234 (157–261) | 208 (157–261) | 260 (158–261) | ns |
aData are expressed as median (1st quartile–3rd quartile)
bMann Whitney U test was used for comparison between HBeAg( +) and (−) groups.
cχ2 test was performed between HBeAg( +) and (−) groups.